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Abstract
Background: Pneumonia is one of the causes of death in infants in developing countries especially Indonesia. Appropriate treatment is needed to decrease mortality rate in children due to pneumonia. Ampicillin is one 
of first choices empirical antibiotic to children with severe pneumonia. The study was aimed to determine 
the failure rate of ampicillin in children with severe pneumonia.
Methods: This study was a descriptive study which used medical records as source of data. Subjects were 
children aged 2–59 months with World Health Organization (WHO) defined with severe pneumonia and 
treated with intravenous ampicillin during January 2014 to July 2015 at Dr. Hasan Sadikin General Hospital 
Bandung. Samples were obtained using total sampling method while variables were analyzed using statistics 
software.
Results: This study acquired 107 patients who met the inclusion criteria with 23.36% of them aged 2–11 
months and 62.21% aged 12–23 months. Majority of subjects were male amounted as 63.55% while female 
occupied 36.45%. Treatment failure on the third day was 45.8% while 16.7% on the sixth day of therapy 
with majority failure due to existence of lower chest indrawing.
Conclusions: Treatment failure on the third and sixth day of therapy still high that is characterized by the 
existence of lower chest indrawing as its main factor. [AMJ.2017;4(1):100–6]
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IntroductionPneumonia is a kind of lung infection 
characterized by inflammation of the lung 
parenchyma tissue caused by infection agents 
such as viruses and bacteria.1,2 In Indonesia, pneumonia is a leading cause of death in children less than 5 years old. An increase 
of period prevalence from 2.1% to 2.7% occurred in 2013.3 Most common pathogen in children less than 5 years old are Streptococcus 
pneumoniae and Haemophillusinfluenzae.1,4,5 
Recent studies were conducted in Indonesia, 
as many as 67.8% Streptococcus pneumoniae in nasopharyngeal specimens in children aged 
2–5 years old with pneumonia.6 Death due to 
pneumonia which is caused by Streptococcus 
pneumoniae and Haemophillus influenzae are 
32.7% and 15.7% respectively.4
Resistance to antibiotics is one of the 
causes of high mortality rate.7 In Asia, 30.1% of Streptococcus pneumoniae is resistant to 
penicillin. Effectiveness of ampicillin against 
Haemophillusinfluenzae is 68.7%, therefore 
the value reflected decreasing ability of ampicillin against Haemophillusinfluenzae.8 
This should be a concern since Streptococcus 
pneumoniae and Haemophillusinfluenzae are 
the most frequent bacteria causing Community 
Acquired Pneumonia (CAP) in children aged 
2–59 months with ampicillin as the first line therapy choice.1,2 Different outcome is 
represented by the study in Lombok which 
showed that serogroup of non-susceptible 
Streptococcus pneumoniae to penicillin could 
reach 2.2%.6 A study conducted in Pakistan9 
among children aged 2–59 months with 
clinical symptoms of pneumonia such as lower 
chest indrawing and rapid breathing that had treatment failure of intravenous ampicillin 
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was 5.8% on third day and 8.6% on sixth day of therapy.9
The study realized the importance of 
researching about treatment failure of 
ampicillin in children with pneumonia due to its increase prevalence, high mortality and the most common etiology such as 
Haemophillusinfluenzae was resistant to ampicillin. In Indonesia, treatment failure 
rate has not been reported; therefore, this study aimed to determine treatment failure of 
intravenous ampicillin in children with severe 
pneumonia aged 2–59 months, exclusively 
patients who were treated in Kenanga Room at Dr. Hasan Sadikin General Hospital Bandung 
from year 2014 to 2015.
Methods
This descriptive study was conducted at Dr. Hasan Sadikin General Hospital Bandung from 3rd September to 20th November 2015. 
Data used in this study were secondary 
data from medical records of patients who 
were treated in Kenanga Room at Dr. Hasan Sadikin General Hospital Bandung from 
January 2014 to July 2015. This study was 
conducted after obtaining the approval from 
Health Research Ethics Committee of Dr. Hasan Sadikin General Hospital Bandung, No: 
LB.04.01/A05/EC/232/VII/2015. Method of 
sampling was conducted by total population method. Minimum sample that required in 
this study were 97 subjects based on sample 
size calculation for descriptive study with 
categorical variables. Sample criteria were 
children aged 2–59 months who met the 
category by World Health Organization (WHO) 
defined with severe pneumonia and treated by 
intravenous ampicillin. Severe pneumonia was 
categorized for patient with rapid breathing 
(aged 2–11 months: ≥50 beats/minute, aged 
11–59 months: ≥ 40 times /minute) and lower 
chest indrawing. Patients with danger signs of very severe pneumonia such as cyanosis, 
inability to breastfeeding, vomiting everything, loss of consciousness, convulsions, and severe 
respiratory distress (aged 2–11 months: ≥60 
beats/minute, age 11–59 months: ≥ 50 times /
minute) were excluded from this study. Patient 
with malnutrition, congenital heart disease, 
tuberculosis, and asthma are also excluded. 
Variables observed in this research 
were age, gender, birth weight, up to date 
immunization, breast feeding, report of 
antibiotics use in past 7 days, referral status, 
treatment failure rate at third and sixth day of 
treatment, antibiotic therapy, and the duration 
of hospitalization. Immunization status was 
defined as the conformity between children 
age and immunization received according 
to the health ministry program. Exclusive 
breastfeeding was defined as breastfeed 
for 6 months without other additional food. 
Treatment failure was determined by looking at patient’s clinical symptoms on third and 
sixth day whether lower chest indrawing, rapid 
breathing, signs of very severe pneumonia, 
death, and fever over 38˚C occurred. Treatment 
failure was monitored on third day due to the 
possibilities of the pathogens which caused 
pneumonia were susceptible to ampicillin, 
hence, the clinical symptoms should be 
improved consequently until the sixth day as 
the subject recovered. Variables were analyzed 
using statistics software.
Result
Total patients with diagnosis of 
bronchopneumonia with International 
Classification of Disease (ICD) criteria 
J.18.0 (bronchopneumonia with unspecified 
organism) during the period of January 2014 
to August 2015 were 616 patients. Subjects 
from January to August 2015 were 191 and 
425 subjects from January to December 2014. 
As of 191 subjects in year 2015, there were 37 
subjects met the inclusion criteria, 3 medical 
records missed, and 151 subjects excluded. 
From 425 subjects in year 2014, there were 70 
subjects met the inclusion criteria, 32 medical 
records missed, and 323 subjects excluded; 
therefore, 107 subjects were obtained 
from January 2014 to August 2015. Clinical 
manifestation of subjects who met inclusion 
criteria was recorded until subject recovered and dismissed from hospital.Based on this study result, median value on 
the subject aged was 12 months, with minimum 
aged was 2 months and maximum aged was 48 
months. From 15 subjects who have history of 
antibiotics usage on the previous week, 5 of 
them were using amoxicillin (Table 1).
On the third day, subjects who experience 
treatment failures were about 49 subjects from 
107 population subjects; hence, the treatment 
failure on third day was 45.8% which is figured 
on table 2. The indicators of treatment failure 
mostly were marked by the existence of lower 
chest indrawing on 37 subjects and rapid 
breathing on 27 subjects. Total subjects who 
have signed of very severe pneumonia were 
9 subjects so that they received antibiotics 
replacement. There were 2 subjects who 
exceeded normal body temperature (≥ 38˚C) 
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and 1 subject passed away on the third day 
(Table 2).
There were 9 subjects who experienced treatment failure on the third day due to very 
severe pneumonia who changed antibiotic 
and one subject passed away. Both of those 
10 subjects were excluded thus the number 
of subject on this study became 97 peoples on 
the sixth day (Table 3).
Subjects who had duration of hospitalization 
were less than six days and otherwise cured 
by doctor, then inserted into group of patients 
who had success treatment because the 
patients dismissal from hospital were linked to 
the absence of lower chest indrawing, no rapid 
breathing, no fever, and subjects were able to 
drink and eat. Hence, there were 67 patients 
who underwent treatment success before day 
6 (Table 4).
On the sixth day, total subjects were 97 
peoples, 16 subjects had treatment failure, 
so the treatment failure rate was 16.5%. 
Treatment failure on the sixth day was 
characterized by the existence of lower chest 
indrawing, rapid breathing, and sign of very severe pneumonia such as severe respiratory 
Table 1 Characteristics of Subject
Characteristics Total (%)
Age (months)     2–11 25 (23.36%)     12–23 67 (62.61%)
     24–35 9 (8.41%)
     36–47 2 (1.86%)
     48–59 4 (3.73%)
Sex     Male 68 (63.55%)     Female 39 (36.45%)
Birth weight (gram)     <2500 7 (6.54%)
     ≥2500 42 (39.25%)
     Unknown 58 (54.2%)
Immunization status     Yes 79 (73.38%)     No 19 (17.75%)
     Unknown 9 (8.41%)
Exclusive Breastfeeding     Yes 72 (67.28%)     No 24 (22.42%)
     Unknown 11 (10.28%)
Report of antibiotic use in past 7 days     Yes 15 (14%)     No 0
     Unknown 92 (86%)Referral     Yes 55 (51.4%)     No 52 (48.6%)
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distress. Most of treatment failure were marked 
by lower chest indrawing and experienced 
by 10 subjects. Antibiotic replacement was 
needed for 8 subjects and there were no 
subjects who had fever.
DiscussionBased on this study result, the highest incidence 
of bronchopneumonia among children 
occurred from age 12 to 23 months which 
was occupied by 67 (62.6%) subjects. These 
findings are in line with the result of National 
Health Research (Riset Kesehatan Dasar, 
Riskesdas) which was held by Indonesian 
Ministry of Health 2013 that showed high 
occurrence of bronchopneumonia among children happened among children aged 12 to 23 months. Nevertheless, this result is slightly 
different with study conducted in Pakistan9 
where majority of study subject amounted 
64% were aged 3 to 11 months.9 
The result presented that based on gender, 
study subjects were dominated by males as 
many as 68 subjects (63.55%). Analogous with another study among children in Pakistan9 
with 60.4% subject are males. Study conducted in Bangladesh10 presented 56.5% subjects are males. Although the results acquired more 
subjects are males, but the different number of 
subjects was not significant.Treatment failure rate on the third day 
reached 45.8%. This result is much higher than similar study conducted in Pakistan9 
where treatment failure on third day was 
5.8%. Study in Pakistan9 showed that subject 
with history of previous antibiotics usage could increase treatment failure rate due 
to the possibilities of pathogen which were 
resistant or stronger. Subjects on this study 
who had history of previous antibiotics and 
experiencing treatment failure on the third 
Table 2 Treatment Failure on 3rd day
Treatment failure on 3rd day N
Lower chest indrawing 13
Rapid breathing 10
Very severe pneumonia 9Any danger sign
     Existence of:
          Lower chest indrawing and rapid breathing 16
          Lower chest indrawing and sign of very severe pneumonia 5
          Lower chest indrawing, rapid breathing, and death 1
          Lower chest indrawing, sign of very severe pneumonia, and fever 2Total 49 (45.8%)
Table 3 Antibiotic Therapy
Antibiotic nAmpicillin 97
Changed antibiotic 9Total 106
Table 4 Length of Stay
Length of stay n
<6 days 67
≥6 days 30Total 97
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day were 5 (33.3%) subjects. 
High failure treatment rate might be 
initiated by the change of pathogen that not 
susceptible to ampicillin. Another possibility 
was etiology of pneumonia caused by serogroup 
Streptococcus pneumoniae that was resistant against ampicillin. Dosage of intravenous 
ampicillin was 25–50mg/kg per injection every 
6 hours. Accordingly, the minimum inhibitory 
concentration (MIC) for susceptible bacteria reached from peak concentration until the last 
half life (≥0.12mcg/ml).2,11 The causal factor that induced high treatment failure could not 
ascertained because subjects did not do lung 
aspiration and test for antibiotic resistance.
On the sixth day of therapy, subjects 
experienced treatment failure as many as 16 
(16.5%) peoples. Another study performed in Pakistan9 acquired treatment failure in sixth 
day was 8.6%. The indicators of treatment 
failure mostly were marked by the existence 
of lower chest indrawn in 10 (62.5%) subjects. The studies performed in Pakistan and other 
countries had similar results which stated 
that lower chest indrawing is the indicator of treatment failure.9,12 Inflammation of the 
lung parenchyma in children with pneumonia 
causes dysfunction in blood oxygen exchange 
then induces hypoxemia. Peripheral 
chemoreceptor located in the carotid body 
is very sensitive to changes in blood oxygen 
levels. When hypoxemia occurs, the carotid 
body will induce respiratory central controller 
to increase the rate of breathing. In children, 
respiratory muscle fibers are composed of 
many types of 2 muscle fibers which are easily 
exhausted that will induce use of respiratory accessory muscle. The use of accessory muscle 
is characterized by clinical sign of lower chest 
indrawing.1
Based on the age, as many as 6 (24%) 
subjects aged 2–11 months and 9 subjects 
aged 12–23 (13.4%) months experienced 
failure treatment on the sixth day. Subjects 
with age less than 12 months had a tendency 
to experience treatment failure.9,13–15 The reasons of treatment failure in young infant 
can be caused by smaller airway, more 
compliant chest wall and poor hypoxic driver. 
These make young infant become vulnerable to respiratory disease.1
Subjects aged less than 24 months 
and exclusively breastfed failed during 
treatment on the sixth day as many as 8 
(19%) subjects. Previous study stated that 
exclusive breastfeeding could decrease the 
risk of treatment failure on the sixth day in 
children aged less than 24 months.9,16,17 This 
phenomenon happened because the exclusive 
breastfeeding itself could increase self-
immunity as natural antimicrobial.18
Children with exclusive breastfeeding 
as many as 46 (63.8%) of 72 subjects were 
hospitalized less than 6 days. Previous study conducted at Dr. Hasan Sadikin General 
Hospital Bandung to children with severe 
pneumonia described that children with 
exclusive breastfeeding had shorter duration 
of hospitalization.19 Exclusive breastfeeding 
can avoid pneumonia and lower the risk of 
morbidity or even mortality due to pneumonia 
among children aged less than 24 months.16,17 
Exclusive breastfeeding itself has natural 
antimicrobial effect which can fight against 
infection caused by Streptococcus pneumonia; 
hence, exclusive breastfeeding is able to 
improve effectiveness of antibiotics, decrease 
MIC (Minimum Inhibitory Concentration), and 
also reduce time needed to kill bacteria.18
Other study showed that children with 
severe pneumonia treated with high dose 
amoxicillin is 80–90 mg/kg per oral every 12 
hours had similar failure rate with intravenous ampicillin.9 This is quite interesting 
considering that 5 subjects in this study had 
history of amoxicillin oral treatment for three 
Table 5 Marked of Treatment Failure on 6th day
Treatment failure on 6th day N
Lower chest indrawing 1
Rapid breathing 3
Very severe pneumonia 3Any danger sign
     Lower chest indrawing and rapid breathing 4
     Lower chest indrawing and very severe pneumonia 5Total 16 (16.5%)
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days, however, the dose given to the patients is 
unknown.The high failure rate indicated the need for 
further research in treatment of children with 
severe pneumonia which considered effective 
and efficient. Study about treatment using 
combination of antibiotics is considered due to 
the killing effects of antibiotics that are faster, 
lowering the cytokines inflammation, and can 
attack organism with broader spectrum.20
Limitations of this study are the data used 
were secondary data so that some of the data 
such as report of antibiotic use in past 7 days, 
birth weight, up to date immunization and 
breastfeeding that are not listed on the medical 
record could not be processed. 
Ampicillin still has high failure rate because 
of the existence of lower chest indrawing during treatment. The failure rate is still high representing lack of effectiveness of treatment 
intravenous ampicillin in children with severe pneumonia. Hence, it requires further research 
regarding to effective antibiotic for severe pneumonia treatment in children.
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